Clinical Trials News - Candlesense

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

WALTHAM, Mass. & GENEVA--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Pa...

Symbol: INVA

2 months ago

Read more businesswire

Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress

MILAN--(BUSINESS WIRE)--Schrödinger announces encouraging initial clinical data from its ongoing Phase 1 dose-escalation study of SGR-1505.

Symbol: SDGR

2 months ago

Read more businesswire

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

Symbol: BMY

2 months ago

Read more businesswire

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

Symbol: BMY

2 months ago

Read more businesswire

Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 Phase 3 clinical trial evaluating the safety...

Symbol: MRK

2 months ago

Read more businesswire

Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 Phase 3 clinical trial evaluating the safety...

Symbol: MRK

2 months ago

Read more businesswire

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone h...

Symbol: ONC

2 months ago

Read more businesswire

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone h...

Symbol: ONC

2 months ago

Read more businesswire

Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the presentation of preclinical pharmacological effect data for BP1.15205, an investigation...

Symbol: HRMY

2 months ago

Read more businesswire

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics today announced that the Company will present three abstracts at the upcoming International Podocyte Conference.

Symbol: TVTX

2 months ago

Read more businesswire